Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine

Science Signaling

Volumn 8, Issue 404, 2015, Pages

  Gassen, Nils C ^a   Fries, Gabriel R ^a,b   Zannas, Anthony S ^a,c   Hartmann, Jakob ^a   Zschocke, Jurgen ^a   Hafner, Kathrin ^a   Carrillo Roa, Tania ^a   Steinbacher, Jessica ^d   Preibinger, S Nicole ^a   Hoeijmakers, Lianne ^a   Knop, Matthias ^a   Weber, Frank ^a   Kloiber, Stefan ^a   Lucae, Susanne ^a   Chrousos, George P ^e   Carell, Thomas ^d   Ising, Marcus ^a   Binder, Elisabeth B ^a,f   Schmidt, Mathias V ^a   Ruegg, Joelle ^g,h   Rein, Theo ^a   more..

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h Swedish Toxicology Sciences Research Center (Swetox)   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIN DEPENDENT KINASE 5; DEXAMETHASONE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FK 506 BINDING PROTEIN; FK506 BINDING PROTEIN 51; FK506 BINDING PROTEIN 52; GENOMIC DNA; HALOPERIDOL; HEAT SHOCK PROTEIN 90; MESSENGER RNA; PAROXETINE; PROTEIN P25; PROTEIN P35; PROTEIN P39; TANESPIMYCIN; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; TACROLIMUS BINDING PROTEIN 5;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ECTOPIC EXPRESSION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPIGENETICS; EX VIVO STUDY; FEMALE; GENETIC TRANSFECTION; HEK293 CELL LINE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; MAJOR DEPRESSION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; ANIMAL; BIOSYNTHESIS; DEPRESSION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HEK293 CELLS; HUMANS; MICE; PAROXETINE; PHOSPHORYLATION; TACROLIMUS BINDING PROTEINS;

EID: 84954470147     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aac7695     Document Type: Article

References (85)

1. T. Klengel, E. B. Binder, Gene-environment interactions in major depressive disorder. Can. J. Psychiatry 58, 76-83 (2013).
2. F. J. Raabe, D. Spengler, Epigenetic risk factors in PTSD and depression. Front. Psychiatry 4, 80 (2013).
3. E. J. Nestler, Epigenetic mechanisms of depression. JAMA Psychiatry 71, 454-456 (2014).
4. S. L. Berger, The complex language of chromatin regulation during transcription. Nature 447, 407-412 (2007).
5. R. Z. Jurkowska, T. P. Jurkowski, A. Jeltsch, Structure and function of mammalian DNA methyltransferases. Chembiochem 12, 206-222 (2011).
6. T. Klengel, E. B. Binder, Gene × environment interactions in the prediction of response to antidepressant treatment. Int. J. Neuropsychopharmacol. 16, 701-711 (2013).
7. V. Vialou, J. Feng, A. J. Robison, E. J. Nestler, Epigenetic mechanisms of depression and antidepressant action. Annu. Rev. Pharmacol. Toxicol. 53, 59-87 (2013).
8. A. Menke, E. B. Binder, Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin. Neurosci. 16, 395-404 (2014).
9. N. M. Tsankova, O. Berton, W. Renthal, A. Kumar, R. L. Neve, E. J. Nestler, Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9, 519-525 (2006).
10. T. Perisic, N. Zimmermann, T. Kirmeier, M. Asmus, F. Tuorto, M. Uhr, F. Holsboer, T. Rein, J. Zschocke, Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 35, 792-805 (2010).
11. M. Fatemi, A. Hermann, H. Gowher, A. Jeltsch, Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur. J. Biochem. 269, 4981-4984 (2002).
12. M. G. Goll, T.H. Bestor, Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005).
13. N. Zimmermann, J. Zschocke, T. Perisic, S. Yu, F. Holsboer, T. Rein, Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem. J. 448, 93-102 (2012).
14. A. J. Sales, C. Biojone, M. S. Terceti, F. S. Guimarães, M. V. M. Gomes, S. R. L. Joca, Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. Br. J. Pharmacol. 164, 1711-1721 (2011).
15. A. Tadi?, L. Müller-Engling, K. F. Schlicht, A. Kotsiari, N. Dreimüller, A. Kleimann, S. Bleich, K. Lieb, H. Frieling, Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol. Psychiatry 19, 281-283 (2014).
16. Y. Dwivedi, H. S. Rizavi, G. N. Pandey, Antidepressants reverse corticosteronemediated decrease in brain-derived neurotrophic factor expression: Differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 139, 1017-1029 (2006).
17. B. G. Dias, S. B. Banerjee, R. S. Duman, V. A. Vaidya, Differential regulation of Brain Derived Neurotrophic Factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 45, 553-563 (2003).
18. W. Qin, H. Leonhardt, G. Pichler, Regulation of DNA methyltransferase 1 by interactions and modifications. Nucleus 2, 392-402 (2011).
19. S. Kar, M. Deb, D. Sengupta, A. Shilpi, S. Parbin, J. Torrisani, S. Pradhan, S. Patra, An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics 7, 994-1007 (2012).
20. J. F. Glickman, J. G. Pavlovich, N. O. Reich, Peptide mapping of the murine DNA methyltransferase reveals a major phosphorylation site and the start of translation. J. Biol. Chem. 272, 17851-17857 (1997).
21. R. Goyal, P. Rathert, H. Laser, H. Gowher, A. Jeltsch, Phosphorylation of serine-515 activates the Mammalian maintenance methyltransferase Dnmt1. Epigenetics 2, 155-160 (2007).
22. G. Lavoie, P.-O. Estève, N. B. Laulan, S. Pradhan, Y. St-Pierre, PKC isoforms interact with and phosphorylate DNMT1. BMC Biol. 9, 31 (2011).
23. G. Lavoie, Y. St-Pierre, Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases. Biochem. Biophys. Res. Commun. 409, 187-192 (2011).
24. E. R. de Kloet, M. Joëls, F. Holsboer, Stress and the brain: From adaptation to disease. Nat. Rev. Neurosci. 6, 463-475 (2005).
25. G. M. Wochnik, J. Rüegg, G. A. Abel, U. Schmidt, F. Holsboer, T. Rein, FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem. 280, 4609-4616 (2005).
26. J.-P. Schülke, G. M. Wochnik, I. Lang-Rollin, N. C. Gassen, R. T. Knapp, B. Berning, A. Yassouridis, T. Rein, Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors. PLOS One 5, e11717 (2010).
27. D. L. Riggs, P. J. Roberts, S. C. Chirillo, J. Cheung-Flynn, V. Prapapanich, T. Ratajczak, R. Gaber, D. Picard, D. F. Smith, The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 22, 1158-1167 (2003).
28. T. R. Hubler, J. G. Scammell, Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 9, 243-252 (2004).
29. R. S. Lee, K. L. K. Tamashiro, X. Yang, R. H. Purcell, A. Harvey, V. L. Willour, Y. Huo, M. Rongione, G. S. Wand, J. B. Potash, Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 151, 4332-4343 (2010).
30. V. Paakinaho, H. Makkonen, T. Jääskeläinen, J. J. Palvimo, Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol. Endocrinol. 24, 511-525 (2010).
31. E. B. Binder, D. Salyakina, P. Lichtner, G. M. Wochnik, M. Ising, B. Pütz, S. Papiol, S. Seaman, S. Lucae, M. A. Kohli, T. Nickel, H. E. Künzel, B. Fuchs, M. Majer, A. Pfennig, N. Kern, J. Brunner, S. Modell, T. Baghai, T. Deiml, P. Zill, B. Bondy, R. Rupprecht, T. Messer, O. Köhnlein, H. Dabitz, T. Brückl, N. Müller, H. Pfister, R. Lieb, J. C. Mueller, E. Lõhmussaar, T. M. Strom, T. Bettecken, T. Meitinger, M. Uhr, T. Rein, F. Holsboer, B. Muller-Myhsok, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36, 1319-1325 (2004).
32. M. Lekman, G. Laje, D. Charney, A. J. Rush, A. F. Wilson, A. J. Sorant, R. Lipsky, S. R. Wisniewski, H. Manji, F. J. McMahon, S. Paddock, The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STARD) Cohort. Biol. Psychiatry 63, 1103-1110 (2008).
33. N. C. Gassen, J. Hartmann, J. Zschocke, J. Stepan, K. Hafner, A. Zellner, T. Kirmeier, L. Kollmannsberger, K. V. Wagner, N. Dedic, G. Balsevich, J. M. Deussing, S. Kloiber, S. Lucae, F. Holsboer, M. Eder, M. Uhr, M. Ising, M. V. Schmidt, T. Rein, Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: Evidence in cells, mice, and humans. PLOS Med. 11, e1001755 (2014).
34. G. Laje, R. H. Perlis, A. J. Rush, F. J. McMahon, Pharmacogenetics studies in STARD: Strengths, limitations, and results. Psychiatr. Serv. 60, 1446-1457 (2009).
35. Y.-F. Zou, F. Wang, X.-L. Feng, W.-F. Li, J.-H. Tao, F.-M. Pan, F. Huang, H. Su, Metaanalysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484, 56-61 (2010).
36. N. C. Gassen, J. Hartmann, A. S. Zannas, A. Kretzschmar, J. Zschocke, G. Maccarrone, K. Hafner, A. Zellner, L. Kollmannsberger, K. V.Wagner, D. Mehta, S. Kloiber, C.W. Turck, S. Lucae, G. P. Chrousos, F. Holsboer, E. B. Binder, M. Ising, M. V. Schmidt, T. Rein, FKBP51 inhibits GSK3b and augments the effects of distinct psychotropic medications. Mol. Psychiatry 10.1038/mp.2015.38 (2015).
37. M. Taipale, G. Tucker, J. Peng, I. Krykbaeva, Z. Y. Lin, B. Larsen, H. Choi, B. Berger, A. C. Gingras, S. Lindquist, A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell 158, 434-448 (2014).
38. Q. Zhou, A. T. Agoston, P. Atadja, W. G. Nelson, N. E. Davidson, Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol. Cancer Res. 6, 873-883 (2008).
39. W. Luo, F. Dou, A. Rodina, S. Chip, J. Kim, Q. Zhao, K. Moulick, J. Aguirre, N. Wu, P. Greengard, G. Chiosis, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. U.S.A. 104, 9511-9516 (2007).
40. J. P. Lopes, P. Agostinho, Cdk5: Multitasking between physiological and pathological conditions. Prog. Neurobiol. 94, 49-63 (2011).
41. U. K. Jinwal, J. Koren III, S. I. Borysov, A. B. Schmid, J. F. Abisambra, L. J. Blair, A. G. Johnson, J. R. Johnson, C. L. Shults, J. C. O'Leary III, Y. Jin, J. Buchner, M. B. Cox, C. A. Dickey, The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J. Neurosci. 30, 591-599 (2010).
42. R. L. Barent, S. C. Nair, D. C. Carr, Y. Ruan, R. A. Rimerman, J. Fulton, Y. Zhang, D. F. Smith, Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes.Mol. Endocrinol. 12, 342-354 (1998).
43. T. Aid, A. Kazantseva, M. Piirsoo, K. Palm, T. Timmusk, Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 85, 525-535 (2007).
44. F. Boulle, D. L. van den Hove, S. B. Jakob, B. P. Rutten, M. Hamon, J. van Os, K.-P. Lesch, L. Lanfumey, H. W. Steinbusch, G. Kenis, Epigenetic regulation of the BDNF gene: Implications for psychiatric disorders. Mol. Psychiatry 17, 584-596 (2012).
45. K. Martinowich, D. Hattori, H. Wu, S. Fouse, F. He, Y. Hu, G. Fan, Y. E. Sun, DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302, 890-893 (2003).
46. F. D. Lubin, T. L. Roth, J. D. Sweatt, Epigenetic regulation of bdnf gene transcription in the consolidation of fear memory. J. Neurosci. 28, 10576-10586 (2008).
47. A. E. West, W. G. Chen, M. B. Dalva, R. E. Dolmetsch, J. M. Kornhauser, A. J. Shaywitz, M. A. Takasu, X. Tao, M. E. Greenberg, Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. U.S.A. 98, 11024-11031 (2001).
48. Y. Wei, P. A. Melas, G. Wegener, A. A. Mathé, C. Lavebratt, Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the Bdnf gene. Int. J. Neuropsychopharmacol. 18, pyu032 (2014).
49. E. B. Binder, R. G. Bradley, W. Liu, M. P. Epstein, T. C. Deveau, K. B. Mercer, Y. Tang, C. F. Gillespie, C. M. Heim, C. B. Nemeroff, A. C. Schwartz, J. F. Cubells, K. J. Ressler, Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299, 1291-1305 (2008).
50. C. F. Gillespie, B. Bradley, K. Mercer, A. K. Smith, K. Conneely, M. Gapen, T. Weiss, A. C. Schwartz, J. F. Cubells, K. J. Ressler, Trauma exposure and stress-related disorders in inner city primary care patients. Gen. Hosp. Psychiatry 31, 505-514 (2009).
51. C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier, K. Egberts, M. Fric, M. Gerlach, C. Greiner, G. Gründer, E. Haen, U. Havemann-Reinecke, S. E. Jaquenoud, H. Kirchherr, G. Laux, U. C. Lutz, T. Messer, M. J. Müller, B. Pfuhlmann, B. Rambeck, P. Riederer, B. Schoppek, J. Stingl, M. Uhr, S. Ulrich, R. Waschgler, G. Zernig, AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44, 195-235 (2011).
52. J. M. Hennings, T. Owashi, E. B. Binder, S. Horstmann, A. Menke, S. Kloiber, T. Dose, B. Wollweber, D. Spieler, T. Messer, R. Lutz, H. Künzel, T. Bierner, T. Pollmächer, H. Pfister, T. Nickel, A. Sonntag, M. Uhr, M. Ising, F. Holsboer, S. Lucae, Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-Findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res. 43, 215-229 (2009).
53. A. Harris, J. Seckl, Glucocorticoids, prenatal stress and the programming of disease. Horm. Behav. 59, 279-289 (2011).
54. N. Provençal, E. B. Binder, The effects of early life stress on the epigenome: From the womb to adulthood and even before. Exp. Neurol. 268, 10-20 (2015).
55. V. G. Moisiadis, S. G. Matthews, Glucocorticoids and fetal programming part 2: Mechanisms. Nat. Rev. Endocrinol. 10, 403-411 (2014).
56. L. E. Cowen, S. Lindquist, Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 309, 2185-2189 (2005).
57. N. Rohner, D. F. Jarosz, J. E. Kowalko, M. Yoshizawa, W. R. Jeffery, R. L. Borowsky, S. Lindquist, C. J. Tabin, Cryptic variation in morphological evolution: HSP90 as a capacitor for loss of eyes in cavefish. Science 342, 1372-1375 (2013).
58. L. Whitesell, S. Santagata, M. L. Mendillo, N. U. Lin, D. A. Proia, S. Lindquist, HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc. Natl. Acad. Sci. U.S.A. 111, 18297-18302 (2014).
59. D. F. Jarosz, S. Lindquist, Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science 330, 1820-1824 (2010).
60. S. L. Rutherford, S. Lindquist, Hsp90 as a capacitor for morphological evolution. Nature 396, 336-342 (1998).
61. H. Pei, L. Li, B. L. Fridley, G. D. Jenkins, K. R. Kalari, W. Lingle, G. Petersen, Z. Lou, L. Wang, FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16, 259-266 (2009).
62. J. C. O'Leary III, S. Dharia, L. J. Blair, S. Brady, A. G. Johnson, M. Peters, J. Cheung-Flynn, M. B. Cox, G. de Erausquin, E. J. Weeber, U. K. Jinwal, C. A. Dickey, A new anti-depressive strategy for the elderly: Ablation of FKBP5/FKBP51. PLOS One 6, e24840 (2011).
63. H. R. Quintá, D. Maschi, C. Gomez-Sanchez, G. Piwien-Pilipuk, M. D. Galigniana, Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. J. Neurochem. 115, 716-734 (2010).
64. C. L. Storer, C. A. Dickey, M. D. Galigniana, T. Rein, M. B. Cox, FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol. Metab. 22, 481-490 (2011).
65. F. Pirkl, J. Buchner, Functional analysis of the hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and cyp40. J. Mol. Biol. 308, 795-806 (2001).
66. L. Sun, H. Zhao, Z. Xu, Q. Liu, Y. Liang, L.Wang, X. Cai, L. Zhang, L. Hu, G. Wang, X. Zha, Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. Cell. Signal. 19, 2255-2263 (2007).
67. J. Hartmann, K. V. Wagner, C. Liebl, S. H. Scharf, X.-D. Wang, M. Wolf, F. Hausch, T. Rein, U. Schmidt, C. Touma, J. Cheung-Flynn, M. B. Cox, D. F. Smith, F. Holsboer, M. B. Müller, M. V. Schmidt, The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62, 332-339 (2012).
68. C. Touma, N. C. Gassen, L. Herrmann, J. Cheung-Flynn, D. R. Büll, I. A. Ionescu, J.-M. Heinzmann, A. Knapman, A. Siebertz, A.-M. Depping, J. Hartmann, F. Hausch, M. V. Schmidt, F. Holsboer, M. Ising, M. B. Cox, U. Schmidt, T. Rein, FK506 binding protein 5 shapes stress responsiveness: Modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry 70, 928-936 (2011).
69. S. Gaali, A. Kirschner, S. Cuboni, J. Hartmann, C. Kozany, G. Balsevich, C. Namendorf, P. Fernandez-Vizarra, C. Sippel, A. S. Zannas, R. Draenert, E. B. Binder, O. F. Almeida, G. Rühter, M. Uhr, M. V. Schmidt, C. Touma, A. Bracher, F. Hausch, Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat. Chem. Biol. 11, 33-37 (2014).
70. A. Roy, E. Gorodetsky, Q. Yuan, D. Goldman, M.-A. Enoch, Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35, 1674-1683 (2010).
71. T. Klengel, D. Mehta, C. Anacker, M. Rex-Haffner, J. C. Pruessner, C. M. Pariante, T. W. Pace, K. B. Mercer, H. S. Mayberg, B. Bradley, C. B. Nemeroff, F. Holsboer, C. M. Heim, K. J. Ressler, T. Rein, E. B. Binder, Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 16, 33-41 (2013).
72. B. Franke, M. Figiel, J. Engele, CNS glia are targets for GDNF and neurturin. Histochem. Cell Biol. 110, 595-601 (1998).
73. B. G. Schumann, P. Jutzi, I. Roditi, Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters . Mol. Biochem. Parasitol. 175, 91-94 (2011).
74. S. van den Heuvel, E. Harlow, Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054 (1993).
75. M. V. Schmidt, V. Sterlemann, K. Ganea, C. Liebl, S. Alam, D. Harbich, M. Greetfeld, M. Uhr, F. Holsboer, M. B. Müller, Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology 32, 417-429 (2007).
76. T. Pfaffeneder, F. Spada, M. Wagner, C. Brandmayr, S. K. Laube, D. Eisen, M. Truss, J. Steinbacher, B. Hackner, O. Kotljarova, D. Schuermann, S. Michalakis, O. Kosmatchev, S. Schiesser, B. Steigenberger, N. Raddaoui, G. Kashiwazaki, U. Müller, C. G. Spruijt, M. Vermeulen, H. Leonhardt, P. Schär, M. Müller, T. Carell, Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat. Chem. Biol. 10, 574-581 (2014).
77. D. Mehta, T. Klengel, K. N. Conneely, A. K. Smith, A. Altmann, T. W. Pace, M. Rex-Haffner, A. Loeschner, M. Gonik, K. B. Mercer, B. Bradley, B. Müller-Myhsok, K. J. Ressler, E. B. Binder, Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc. Natl. Acad. Sci. U.S.A. 110, 8302-8307 (2013).
78. M. J. Aryee, A. E. Jaffe, H. Corrada-Bravo, C. Ladd-Acosta, A. P. Feinberg, K. D. Hansen, R. A. Irizarry, Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363-1369 (2014).
79. E. M. Price, A. M. Cotton, L. L. Lam, P. Farré, E. Emberly, C. J. Brown, W. P. Robinson, M. S. Kobor, Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 6, 4 (2013).
80. Y.-A. Chen, M. Lemire, S. Choufani, D. T. Butcher, D. Grafodatskaya, B. W. Zanke, S. Gallinger, T. J. Hudson, R. Weksberg, Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8, 203-209 (2013).
81. J.-P. Fortin, A. Labbe, M. Lemire, B. W. Zanke, T. J. Hudson, E. J. Fertig, C. M. Greenwood, K. D. Hansen, Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 15, 503 (2014).
82. W. E. Johnson, C. Li, A. Rabinovic, Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).
83. W. Huber, A. von Heydebreck, H. Sültmann, A. Poustka, M. Vingron, Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18, S96-S104 (2002).
84. P. Du, X. Zhang, C.-C. Huang, N. Jafari, W. A. Kibbe, L. Hou, S. M. Lin, Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
85. A. Menke, J. Arloth, B. Pütz, P. Weber, T. Klengel, D. Mehta, M. Gonik, M. Rex-Haffner, J. Rubel, M. Uhr, S. Lucae, J. M. Deussing, B. Müller-Myhsok, F. Holsboer, E. B. Binder, Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37, 1455-1464 (2012).